These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 2121921

  • 21. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
    Schroeder TJ, First MR, Mansour ME, Alexander JW, Penn I.
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
    [Abstract] [Full Text] [Related]

  • 22. Adjuncts to triple-drug therapy after cardiac transplantation: a comparison of Nashville rabbit antithymocyte serum to OKT3.
    Aziz S, Kruse AP, Roby PV, Allen MD, Khan K, Fishbein D.
    Transplant Proc; 1994 Oct; 26(5):2721-3. PubMed ID: 7940852
    [No Abstract] [Full Text] [Related]

  • 23. Comparison of immunosuppression therapy following heart transplantation: pretransfusion/azathioprine/ATG/prednisone versus cyclosporine/prednisone.
    Barnhart GR, Goldman MH, Hastillo A, Szentpetery S, Wolfgang T, Thompson J, Mohanakumar T, Katz MR, Rider S, Hanrahan J.
    J Heart Transplant; 1985 Oct; 4(4):381-4. PubMed ID: 3916511
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Influence of induction therapy on rejection and survival in heart transplantation.
    Almenar L, García-Palomar C, Martínez-Dolz L, Chamorro C, Moro J, Zorio E, Arnau MA, Rueda J, Osa A, Cardo ML.
    Transplant Proc; 2005 Nov; 37(9):4024-7. PubMed ID: 16386616
    [Abstract] [Full Text] [Related]

  • 26. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
    Kahana L, Narvarte J, Ackermann J, LeFor W, Weinstein S, Wright C, deQuesada A, Baxter J, Shires D.
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
    [Abstract] [Full Text] [Related]

  • 27. HLA-DR incompatibility predicts heart transplant rejection independent of immunosuppressive prophylaxis.
    Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson M, Heroux A, Kao W, Mullen GM, Radvany R, Robinson J.
    J Heart Lung Transplant; 1993 Nov; 12(5):779-89. PubMed ID: 8241215
    [Abstract] [Full Text] [Related]

  • 28. How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation?
    Wagner FM, Reichenspurner H, Uberfuhr P, Kur F, Kaulbach HG, Meiser BM, Ziegler U, Reichart B.
    J Heart Lung Transplant; 1994 Nov; 13(3):438-42; discussion 442-3. PubMed ID: 8061020
    [Abstract] [Full Text] [Related]

  • 29. Quadruple immunosuppression: comparison of OKT3 and Minnesota antilymphocyte globulin.
    Light JA, Khawand N, Aquino A, Ali A, Korb S.
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):10-3. PubMed ID: 2510505
    [Abstract] [Full Text] [Related]

  • 30. Increased cardiac allograft rejection in female heart transplant recipients.
    Crandall BG, Renlund DG, O'Connell JB, Burton NA, Jones KW, Gay WA, Doty DB, Karwande SV, Lee HR, Holland C.
    J Heart Transplant; 1988 Nov; 7(6):419-23. PubMed ID: 3062147
    [Abstract] [Full Text] [Related]

  • 31. A prospective randomized controlled study on the efficacy and tolerance of two antilymphocytic globulins in the prevention of rejection in first-heart transplant recipients.
    Schnetzler B, Leger P, Völp A, Dorent R, Pavie A, Gandjbakhch I.
    Transpl Int; 2002 Jun; 15(6):317-25. PubMed ID: 12072903
    [Abstract] [Full Text] [Related]

  • 32. Steroid-free maintenance immunotherapy: Minneapolis Heart Institute experience.
    Pritzker MR, Lake KD, Reutzel TJ, Hoffman FM, Jorgensen CR, Pederson W, Emery RW.
    J Heart Lung Transplant; 1992 Jun; 11(2 Pt 2):415-20. PubMed ID: 1571339
    [Abstract] [Full Text] [Related]

  • 33. Induction immunosuppression with OKT3 monoclonal antibody in cardiac transplant recipients.
    Pulpón LA, Domínguez P, Cháfer M, Segovia J, Crespo MG, Pradas G, Burgos R, Figuera D.
    Transplant Proc; 1990 Oct; 22(5):2319. PubMed ID: 2120816
    [No Abstract] [Full Text] [Related]

  • 34. The incidence and quantity of antiidiotypic antibody formation after OKT3 monoclonal therapy in heart-transplant recipients.
    Hesse CJ, Heyse P, Stolk BJ, Balk AH, Jutte NH, Mochtar B, Weimar W.
    Transplant Proc; 1990 Aug; 22(4):1772-3. PubMed ID: 2117805
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. The duration of administration of monoclonal antibody OKT3 for induction immunosuppression after heart transplantation.
    Aleksic I, Freimark D, Blanche C, Czer LS, Dalichau H, Valenza M, Takkenberg JJ, Trento A.
    Thorac Cardiovasc Surg; 1997 Aug; 45(4):190-5. PubMed ID: 9323821
    [Abstract] [Full Text] [Related]

  • 37. Independent risk factors predicting acute graft rejection in cardiac transplant recipients treated by triple drug immunosuppression.
    Laufer G, Miholic J, Laczkovics A, Wollenek G, Holzinger C, Hajek-Rosenmeier A, Wuzl G, Schreiner W, Buxbaum P, Wolner E.
    J Thorac Cardiovasc Surg; 1989 Dec; 98(6):1113-21. PubMed ID: 2586129
    [Abstract] [Full Text] [Related]

  • 38. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol.
    Ladowski JS, Dillon T, Schatzlein MH, Peterson AC, Deschner WP, Beatty L, Sullivan M, Scheeringa RH, Clark WR.
    J Cardiovasc Surg (Torino); 1993 Apr; 34(2):135-40. PubMed ID: 8320247
    [Abstract] [Full Text] [Related]

  • 39. Selective OKT3 induction therapy in adult cadaveric-donor renal transplant recipients.
    Thistlethwaite JR, Heffron TG, Stuart JK, Buckingham M, Stuart FP.
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):28-34. PubMed ID: 2510508
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.